sugammadex
Brand: Bridion
Prototype Drug
Drug Class: neuromuscular blockade reversal agent
Drug Family: reversal agent
Subclass: selective relaxant binding agent; modified gamma-cyclodextrin
Organ Systems: cnsmusculoskeletal
Mechanism of Action
Modified gamma-cyclodextrin that forms tight inclusion complexes with rocuronium and vecuronium, encapsulating the NMBA molecule and preventing NMJ binding. Creates concentration gradient pulling NMBAs away from NMJ into plasma, achieving complete reversal at any depth of blockade.
rocuronium (encapsulation)vecuronium (encapsulation)
Indications
- reversal of rocuronium-induced neuromuscular blockade (any depth)
- reversal of vecuronium-induced blockade
- emergency reversal of profound rocuronium blockade
Contraindications
- hypersensitivity to sugammadex
Adverse Effects
Common
- nausea
- vomiting
- dysgeusia
- headache
Serious
- anaphylaxis (rare; estimated 0.039%)
- bradycardia
- recurrence of blockade if dose is insufficient
Pharmacokinetics (ADME)
| Absorption | IV only |
| Distribution | minimal protein binding; Vd ~11-14 L |
| Metabolism | not metabolized; excreted as rocuronium-sugammadex complex |
| Excretion | renal (primarily as intact complex) |
| Half-life | 1.8 hours |
| Onset | TOF recovery within 3 minutes (16 mg/kg) to 15 minutes (2-4 mg/kg) |
| Peak | minutes after administration |
| Duration | dose-dependent |
| Protein Binding | minimal |
| Vd | 11-14 L |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| progestogen-only contraceptives | sugammadex can bind and reduce efficacy; use additional contraception for 7 days | moderate |
| hormonal contraceptives (oral) | requires extra non-hormonal contraception for 7 days | moderate |
Nursing Considerations
- Dose-dependent: 2 mg/kg for moderate blockade (2 twitches on TOF), 4 mg/kg for shallow, 16 mg/kg for immediate/deep reversal.
- Instruct female patients to use additional non-hormonal contraception for 7 days after receiving sugammadex.
- Assess airway, respiratory rate, SpO2, and TOF after administration to confirm adequate reversal.
- Anaphylaxis risk is low but epinephrine must be available in all anesthesia settings.
Clinical Pearls
- Sugammadex revolutionized anesthesia by providing rapid, complete reversal of rocuronium at any depth; in cannot-intubate-cannot-oxygenate scenario, 16 mg/kg reverses RSI-dose rocuronium within 3 minutes.
- Unlike neostigmine, sugammadex does not require anticholinergic co-administration (no muscarinic effects), simplifying the reversal process.
Safety Profile
Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.